Proliferation News and Research

RSS

Breakthrough in understanding the phenomenon of nucleolar dominance

Since the machinery involved in nucleolar dominance is some of the same machinery that can go haywire in diseases such as cancer, Pikaard and his collaborators' research may have important implications for applied medical research.

5 Dec 2008

New insights into cell division

Biologists have discovered a mechanism that is critical to cytokinesis -- nature's completion of mitosis, where a cell divides into two identical daughter cells.

5 Dec 2008

Cancer stem-cell model tested by University of Michigan researchers

One of the most promising new ideas about the causes of cancer, known as the cancer stem-cell model, must be reassessed because it is based largely on evidence from a laboratory test that is surprisingly flawed when applied to some cancers, University of Michigan researchers have concluded.

3 Dec 2008

Children walking less

Days when schoolchildren walked to neighbourhood schools are long gone.

3 Dec 2008

New set of controls for stem cells discovered

Natural changes in voltage that occur across the membrane of adult human stem cells are a powerful controlling factor in the process by which these stem cells differentiate, according to research published by Tufts University scientists.

3 Dec 2008

Broccoli compound, indole-3-carbinol targets key enzyme in late-stage cancer

An anti-cancer compound found in broccoli and cabbage works by lowering the activity of an enzyme associated with rapidly advancing breast cancer, according to a University of California, Berkeley, study appearing this week in the online early edition of the journal Proceedings of the National Academy of Sciences.

3 Dec 2008

FDA accepts Zevalin supplemental biologics license application

Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.

1 Dec 2008

EGFR inhibitors show promise for obesity

Once-promising drugs that were abandoned in the fight against breast cancer still could be effective in obese patients, new research suggests.

1 Dec 2008

MorphoSys granted U.S. patent on antibodies against GM-CSF to treat inflammatory disorders

MorphoSys AG and the University of Melbourne announced today that the U.S. Patent & Trademark Office (USPTO) has confirmed that it will issue U.S. Patent No. 7,455,836, covering key uses of antibodies against GM-CSF.

25 Nov 2008

Novel device enhances efficacy of standard chemotherapy

NovoCure Ltd. presented results yesterday evaluating the Novo-TTF device in vitro and in a pilot clinical trial that showed the device enhanced the efficacy of standard chemotherapy (temozolomide) treatment in newly-diagnosed glioblastoma multiforme (GBM) patients.

24 Nov 2008

Discovery of novel approach to suppress prostate cancer progression

Researchers at the University of Southern California (USC) have found that inactivating a specific biomarker for aggressive prostate cancer blocks the development of prostate cancer in animal models.

24 Nov 2008

Evidence of retina self-repair in mammals

Researchers at the University of Washington (UW) have reported for the first time that mammals can be stimulated to regrow inner nerve cells in their damaged retinas.

24 Nov 2008

New insight into the response of human skin to radiation

Scientists have new insight into the response of human skin to radiation and what drives the most aggressive and deadly form of skin cancer.

20 Nov 2008

FDA approves GSK's Promacta (Eltrombopag)

GlaxoSmithKline has announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

20 Nov 2008

New compounds break up cancer-causing protein STAT3 and destroy breast cancer tumors.

Two new compounds created by a University of Central Florida professor show early promise for destroying breast cancer tumors.

19 Nov 2008

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

19 Nov 2008

Cancer drug bevacizumab linked to significantly increased risk of blood clots

An analysis of randomized controlled trials indicates that use of the cancer drug bevacizumab is associated with an increased risk of venous thromboembolism (blood clots in the deep veins of the legs or in the lungs), according to an article in the November 19 issue of JAMA, the Journal of the American Medical Association.

18 Nov 2008

Discovery of 13 new tumor-suppressor genes in liver cancer

Over the years, hunting for cancer-related genes and understanding how they work has been an important, although time-consuming, exercise.

18 Nov 2008

Two common cancer drugs prevent, reverse type 1 diabetes

Two common cancer drugs have been shown to both prevent and reverse type 1 diabetes in a mouse model of the disease, according to research conducted at the University of California, San Francisco.

18 Nov 2008

Exercise increases brain growth factor and receptors, prevents stem cell drop in middle age

A new study confirms that exercise can reverse the age-related decline in the production of neural stem cells in the hippocampus of the mouse brain, and suggests that this happens because exercise restores a brain chemical which promotes the production and maturation of new stem cells.

18 Nov 2008